The Benefit of a Deep Cleansing Gel in the Management of Mild to Moderate Truncal Acne
Assessment of the Benefit of a Deep Cleansing Gel Containing Salicylic Acid 2%, Zinc Gluconate 0.2% and Lipohydroxy Acids 0.05% in Patients With Mild to Moderate Truncal Acne: Results From an Exploratory Study
1 other identifier
observational
35
1 country
1
Brief Summary
Acne vulgaris is a chronic inflammatory disease, mainly of the face, but also of the trunk. Acne may be caused by internal and external factors. Only a very small amount of data exists concerning truncal acne. The condition affects about 9% of the population worldwide, with 50% of subjects with facial acne also presenting with truncal acne. Until recently, clinicians frequently followed the same therapeutic approach as for facial acne, with treatment adherence remaining an issue. This study assessed assessed the benefit of a cleansing gel containing salicylic acid 2%, zinc gluconate 0.2% and Lipo hydroxy acids (LHA) 0.05%, used daily for 84 days in mild to moderate truncal acne.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Oct 2019
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
November 30, 2020
CompletedFirst Submitted
Initial submission to the registry
September 25, 2022
CompletedFirst Posted
Study publicly available on registry
October 18, 2022
CompletedOctober 18, 2022
September 1, 2022
1.2 years
September 25, 2022
October 14, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Investigator global assessment
Scale 0=absent to 5=very serious
baseline
Investigator global assessment
Scale 0=absent to 5=very serious
Day 42
Investigator global assessment
Scale 0=absent to 5=very serious
Day 84
Secondary Outcomes (21)
inflammatory lesion count
baseline
inflammatory lesion count
Day 42
inflammatory lesion count
Day 84
non-inflammatory lesion count
baseline
non-inflammatory lesion count
Day 42
- +16 more secondary outcomes
Interventions
daily use
Eligibility Criteria
adult female or males with subjects with truncal acne
You may qualify if:
- above 18 years
- truncal acne
You may not qualify if:
- \- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CIDP
Rio de Janeiro, 20231-048, Brazil
Related Publications (1)
Towersey L, Correia P, Fajgenbaum Feiges M, Euzebio Goncalves Junior J, Sant'Anna B, Kerob D, Le Floc'h C. Assessment of the Benefit of a Deep Cleansing Gel Containing Salicylic Acid 2%, Zinc Gluconate 0.2% and Lipohydroxy Acids 0.05% in Patients with Mild to Moderate Truncal Acne: Results from an Exploratory Study. Clin Cosmet Investig Dermatol. 2023 Jan 18;16:119-123. doi: 10.2147/CCID.S394123. eCollection 2023.
PMID: 36698447DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Delphine Kerob, MD
La Roche-Posay Laboratoire Dermatologique
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 25, 2022
First Posted
October 18, 2022
Study Start
October 1, 2019
Primary Completion
November 30, 2020
Study Completion
November 30, 2020
Last Updated
October 18, 2022
Record last verified: 2022-09
Data Sharing
- IPD Sharing
- Will not share